Director Jamere Jackson filed a Form 4 with the SEC on November 17, 2026, disclosing the acquisition of Eli Lilly & Co common stock on November 16, 2026.

Key Highlights

  • Reporting person: Jamere Jackson, identified as a Director of Eli Lilly & Co (NYSE:LLY).
  • Transaction: 167.6364 shares of common stock acquired (code A) on November 16, 2026.
  • Price per share: $1,431.67, as reported in the filing.
  • Resulting ownership: 9,861.2537 shares of common stock held directly following the transaction.
  • Filing date: November 17, 2026, signed by Jonathan Groff on behalf of Jamere Jackson pursuant to authorization on file.

Jamere Jackson's November 2026 Common Stock Acquisition at Eli Lilly

According to the Form 4 filing, Jamere Jackson, a Director of Eli Lilly & Co, acquired 167.6364 shares of Eli Lilly common stock on November 16, 2026. The transaction was recorded with a price of $1,431.67 per share and a transaction code of "A," indicating an acquisition. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the relevant checkbox was not checked.

Following the reported transaction, the filing states that Jackson directly beneficially owned 9,861.2537 shares of Eli Lilly common stock. No derivative securities transactions were reported in Table II of the filing. The form was filed on November 17, 2026, and was signed by Jonathan Groff for Jamere Jackson pursuant to an authorization on file.

No amendments to a prior filing were indicated, and the filing states it was made by one reporting person. The issuer is identified as Eli Lilly & Co, trading under the ticker symbol LLY on the NYSE.

What Was Disclosed

The filing disclosed that Director Jamere Jackson acquired 167.6364 shares of Eli Lilly & Co common stock on November 16, 2026, at $1,431.67 per share, bringing his directly held total to 9,861.2537 shares.